Nasus Pharma developed Taffix®-An innovative nasal powder personal spray comprised of low-pH Hypromellose which forms a protective mechanical barrier that prevents viruses from engaging with nasal cells and deactivates viruses. Taffix® was found to be a significant protective tool for preventing airborne viral infections, including by SARS-CoV-2 in addition to the multiple preventive measures taken today. Taffix is safe and biocompatible. Nasus has tested its products in several in vitro efficacy studies with multiple virus strains, including a few variants of SARS-CoV-2 (Hong Kong/VM20001061/2020; Alpha; Beta and Delta Israel isolate; lentivirus and influenza). Taffix® spray blocked passage of all four tested SARS-CoV-2 variants, as demonstrated by a 99%-100% reduction of recoverable viral RNA from Vero-E6 cells or by plaque assay, Taffix® was tested in human real-life, high infection risk setting during the COVID-19 pandemic (September 2020): In a prospective two-week user survey completed by 243 individuals participating in a two-day mass-gathering event in a highly endemic community, none of the 81 individuals who regularly applied Taffix® nasal spray during the event and the subsequent two weeks reported on SARS-CoV-2 infection (verified by PCR). In contrast, of the 18 individuals who tested SARS-CoV-2-positive in the subsequent two weeks, 16 (98%) did not use Taffix® and the remaining two individuals report using it once or twice in the study period? No side effects were reported.
Taffix® is legally marketed in Europe, Israel and more and additional clinical data is being collected.
Share this article
Select your language of interest to view the total content in your interested language